TIDMSBTX
RNS Number : 4831S
SkinBioTherapeutics PLC
03 October 2017
SkinBioTherapeutics plc
SkinBiotix(R) platform passes external cytotoxicity tests
Scientific progress on track
Manchester, UK - 3 October 2017 - SkinBioTherapeutics plc (AIM:
SBTX, the "Company"), a life science company focused on skin
health, has passed third party cellular toxicity tests for its
SkinBiotix(R) technology, confirming previous in-house observations
on its safety and applicability.
The Company has also been progressing its three programmes and
is on track to hit its key milestone of first studies in man in
2018.
Cytotoxicity studies
The studies were conducted by Charles River, a Contract Research
Organisation, in accordance with the OECD Principles of Good
Laboratory Practice.
The objective of the toxicity tests was to determine if there
were any adverse biological reactions from mammalian cell cultures
following the use of SkinBioTherapeutics' SkinBiotix(R)
technology.
Following incubation for 24 hours, no cytotoxicity was observed
e.g., malformation of cells or cell degeneration. The data confirm
SkinBioTherapeutics' in-house observations on how mammalian skin
cells and fibroblasts respond to being exposed to SkinBiotix(R).
This further supports the principle of SkinBiotix(R)'s suitability
for use in skin care applications.
Two further tests, phototoxicity and in vitro ocular toxicity
are scheduled. These results will be reported when the data is
received.
Scientific update
As outlined at IPO in April 2017, SkinBioTherapeutics has been
concentrating on further developing its technology towards the
three applications in skin care, anti-infection and skin
repair.
The positive cytotoxicity result above is a key milestone.
However, other work is progressing well and the Company has
summarised this below:
- Manufacture: work on scale-up has been initiated, confirmed by
the successful manufacture of SkinBiotix(R) by an external
partner
- Pilot scale formulation has been initiated by an external
partner with expertise in cosmetic formulation development. Phase
one of three is complete; testing of solubility and preservative
requirements of the technology. Phase two, identifying a final
blend for testing, is currently underway
- Early stage commercial discussions are ongoing with both
potential manufacturing partners as well as potential licensees
- Anti-infection and eczema programmes
o A 'time-course' study, has confirmed that the frequency of
application required for protection is three times daily.
Therefore, protection against Staphylococcus aureus infection for
both eczema and infection programmes requires application every
five hours*
- Regulatory process has commenced and a regulatory consultant has been appointed
- Ongoing scientific studies:
o Defining dosage is complete - for all three applications.
SkinBioTherapeutics has finalised a dosing level at which the
technology will be used which maintains the viability of the skin
cells
o Confirmation of the modifying property of SkinBiotix(R) on
protein composition of the skin, increasing the expression of
Claudin 4, an essential component in tight junctions which are
critical for the barrier characteristic of skin
*These data were recently presented at a Wellcome Trust
conference: "Host Microbiome Interactions in Health and
Disease".
Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:
"This announcement demonstrates the excellent progress
SkinBioTherapeutics is making at all levels - scientific,
development, manufacture and commercial.
"The result from the cytotoxicity testing by Charles River is
essential external validation of our SkinBiotix(R) platform. This
was one of the key milestones to pass and was highlighted as such
at the IPO. Its passing marks a critical step in our progression
and the transitioning of the technology into human validation
studies.
"Operationally, we are on track. The development programmes are
progressing well, we are generating further scientific data on
SkinBiotix(R) confirming its suitability for application to skin,
and industry awareness of our technology is growing."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0)
Dr. Cath O'Neill, CEO 161 468 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP Tel: +44 (0)
Tony Rawlinson / Emma Earl / 20 7213 0880
Richard Nash
Turner Pope Investments Tel: +44 (0)
Ben Turner / James Pope 20 3621 4120
Instinctif Partners Tel: +44 (0)
Melanie Toyne-Sewell / Alex 20 7457 2020
Shaw / Deborah Bell SkinBio@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Its dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about Charles Rivers' unique portfolio and breadth of
services, visit www.criver.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESUUVBRBWARRAA
(END) Dow Jones Newswires
October 03, 2017 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024